combining glp-1 receptor agonist with dpp-4 inhibitor not recommended guideline Can dipeptidyl peptidase‑4 (DPP‑4) inhibitors be combined semaglutide ( GLP‑1 agonist)? Effect of combination treatment with
Description
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
Pramlintide and GLP-1 analogs may delay gastric emptying in diabetics
Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6
doi: 10.1210/endo.139.7.6092
